DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
SCDAA Masterclass Speaker Series: All Things Considered – SCD Treatment: A Personal Choice
SCDAA’s First Masterclass on the Cusp of a Cure
All Things Considered – SCD Treatment: A Personal Choice
Thursday, August 24, 2023 at 3-4 p.m. EST
Co-hosts Teonna Woolford and Dr. Wanda Whitten-Shurney will discuss the many considerations that go into choosing disease modifying treatments or curative therapies. Panelists include speakers who will share their lived SCD experiences, the choices they made, and why.
+myBinderRelated Content
-
Community CenterWhat it’s like to be 17 and living with sickle cell diseaseTre Adegoroye is 17 and was diagnosed wi...
-
news & eventsFighting sickle cell disease by looking back to babyhoodFast-track research focused on developin...
-
news & eventsImara Reports Favorable Preclinical and Phase 1 Data on IMR-687 in Sickle Cell DiseaseImara Inc. today announced it will repor...
-
education & researchSickle Cell Disease Coalition: Build Your Own SCD School BinderThe Build Your Own SCD School Binder off...
-
news & eventsSiklos (hydroxyurea) now available through ProCare Pharmacy Care’s Siklos At Home programMedunik USA announced today that...
-
news & eventsFirst Sickle Cell Patient Dosed in Phase 2a of IMR-687This morning, Imara Inc. announced that ...
-
news & eventsBioverativ and Bicycle Therapeutics Enter into Strategic Research Collaboration to Develop Therapies for Hemophilia ...Bioverativ Inc. (NASDAQ: BIVV), a global...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.